Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...

Cibc World Markets Corp bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the fourth quarter, ...

Highlights,Swiss National Bank expanded its holdings in Avidity Biosciences Inc. during the fourth quarter.,Multiple ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the thirteen research ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of ...

Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on ...

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago.

SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...